Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26B1 | Q9NR63 | 7/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 7/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.44 |
| ▸ | KLK1 | P06870 | 2/20 | 0.44 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.44 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.40 |
| ▸ | RARA | P10276 | 2/20 | 0.39 |
| ▸ | RARB | P10826 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9850145 | 0.88 | SSTR5 (0.46) | CYP26B1CYP26A1SSTR5RARARARB | |
| SCHEMBL5736859 | 0.87 | SSTR5 (0.38) | CYP26B1CYP26A1PRSS1KLK1TMPRSS2 | |
| SCHEMBL9850207 | 0.84 | RARB (0.47) | CYP26A1PRSS1RARARARBHIF1A | |
| SCHEMBL8458446 | 0.83 | RARA (0.57) | PRSS1RARARARBHIF1A | |
| SCHEMBL9850206 | 0.83 | HIF1A (0.49) | RARARARBHIF1A | |
| SCHEMBL6143586 | 0.82 | CYP26A1 (0.53) | CYP26B1CYP26A1SSTR5AKR1B1HIF1A | |
| SCHEMBL9850151 | 0.82 | MAPT (0.48) | PRSS1RARARARBHIF1A | |
| SCHEMBL4842011 | 0.80 | CYP26A1 (0.51) | CYP26B1CYP26A1PRSS1KLK1TMPRSS2 | |
| SCHEMBL8759232 | 0.78 | RARB (0.47) | CYP26B1CYP26A1RARARARBHIF1A | |
| SCHEMBL5737195 | 0.77 | CYP26A1 (0.47) | CYP26B1CYP26A1SSTR5AKR1B1RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1366036-B1 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN INC (US) | 2006-01-11 | — | — | EP | claimed |
| EP-1366036-A2 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | Allergan, Inc. (US) | 2003-12-03 | — | — | EP | claimed |
| EP-1322631-A2 | METHODS OF PROVIDING AND USING COMPOUNDS ( RETINOIDS ) HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | Allergan, Inc. (US) | 2003-07-02 | — | — | EP | claimed |
| US-20030078270-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2003-04-24 | — | — | US | claimed |
| US-20020132796-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2002-09-19 | — | — | US | claimed |
| US-6369225-B1 | ENZYME INHIBITORS | ALLERGAN SALES, INC. | 2002-04-09 | — | — | US | claimed |
| WO-2002026727-A2 | METHODS OF PROVIDING AND USING COMPOUNDS (RETINOIDS) HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-04-04 | — | — | WO | claimed |
| WO-2002018361-A2 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-03-07 | — | — | WO | claimed |
| US-6313107-B1 | ADMINISTERING TO MAMMAL TO TREAT DISEASES RESPONSIVE TO TREATMENT BY RETINOIDS | ALLERGAN SALES, INC. | 2001-11-06 | — | — | US | claimed |
| EP-1366036-B1 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN INC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-6855512-B2 | Methods for identifying inhibitors of cytochrome P450RAI | ALLERGAN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-6713647-B2 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2004-03-30 | — | — | US | disclosed |
| EP-1366036-A2 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | Allergan, Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20030186947-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2002026727-A2 | METHODS OF PROVIDING AND USING COMPOUNDS (RETINOIDS) HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6359135-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2002-03-19 | — | — | US | disclosed |
| WO-2002018361-A2 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6313107-B1 | ADMINISTERING TO MAMMAL TO TREAT DISEASES RESPONSIVE TO TREATMENT BY RETINOIDS | ALLERGAN SALES, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6303785-B1 | SUBSTITUTED N-CYCLOPROPYLTETRAHYDROISOQUINOLINES | ALLERGAN SALES, INC. | 2001-10-16 | — | — | US | disclosed |
| US-6252090-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078270-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | CYP26B1, CYP21A2, ALDH1A2 | CYP26B1 1/4885CYP26A1 4/4885PRSS1 1382/4885 |
| US-20020132796-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | CYP26B1, CYP21A2, ALDH1A2 | CYP26B1 1/4885CYP26A1 4/4885PRSS1 1382/4885 |
| US-20030186947-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | RARA, RARB, RARG | CYP26B1 5/4885CYP26A1 6/4885PRSS1 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.